Fig. 6
From: A 3,2-Hydroxypyridinone-based Decorporation Agent that Removes Uranium from Bones In Vivo
In vivo decorporation efficiency and in vitro desorption efficiency results. a–d Removal efficiency of U(VI) deposited in the kidneys and femurs compared to the control group. For the single-dose group, mice were ip injected (193 μmol kg−1, molar ratio 92:1) or oral administered (644 μmol kg−1, molar ratio 307:1) with ligands after the iv injection of U(VI) (0.5 mg U(VI) kg−1) and then were killed 24 h later. e The urine & feces excretion percentage for the group 5LIO-1-Cm-3,2-HOPO and 5LIO-(Me-3,2-HOPO) treated with single-dose ip injection or oral administration. f Removal efficiency of U(VI) deposited in the kidneys and femurs compared to the control group, for the multiple-dose group. Mice were given the ligand by ip (97 μmol kg−1, molar ratio 46:1) injection at 3 min, 6 h, 24 h, and 48 h, or at 1 h, 7 h, 25 h, and 49 h after the iv injection of U(VI) (0.5 mg U(VI) kg−1) and were killed 72 h later. g Removal efficiency of U(VI) deposited in the kidneys and femurs compared to the control group, for the delayed multiple-dose group. Mice were given the ligand by ip (193 μmol kg−1, molar ratio 92:1) injection at 6 h, 12 h, 30 h, and 54 h (6 h delayed multiple-dose group), or at 12, 18, 36, and 60 h (12 h delayed multiple-dose group), or at 24, 30, 48, and 72 h (24 h delayed multiple-dose group) after the iv injection of U(VI) (0.5 mg U(VI) kg−1) and were killed 7 d later. *p < 0.05, **p < 0.01, ***p < 0.001 vs. U(VI)-treated control, paired-sample T-test for independent-samples, n = 5 mice. Bars indicate SD, n = 5 mice. h U(VI) desorption efficiency from HAP using 5LIO-1-Cm-3,2-HOPO, 5LIO-(Me-3,2-HOPO) or ZnNa3-DTPA. Source data are provided as a Source Data file
